Bharatbook.com announces a new report on "N30 Pharmaceuticals - Product Pipeline Review " which provides data on the N30 Pharmaceuticals’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Oct 14, 2013 : Bharat Book Bureau presents the new report, on ‘N30 Pharmaceuticals – Product Pipeline Review’ provides data on the N30 Pharmaceuticals’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, N30 Pharmaceuticals’s corporate website, SEC filings, investor presentations and featured press releases, both from N30 Pharmaceuticals and industry-specific third party sources, put together by Global Markets Direct’s team.
- N30 Pharmaceuticals – Brief N30 Pharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of N30 Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of N30 Pharmaceuticals with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the N30 Pharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate N30 Pharmaceuticals’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of N30 Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the N30 Pharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with N30 Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of N30 Pharmaceuticals and identify potential opportunities in those areas.
Table of contents :
Table of Contents 2
List of Tables 4
List of Figures 4
N30 Pharmaceuticals Snapshot 5
N30 Pharmaceuticals Overview 5
Key Information 5
Key Facts 5
N30 Pharmaceuticals – Research and Development Overview 6
Key Therapeutic Areas 6
N30 Pharmaceuticals – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
N30 Pharmaceuticals – Pipeline Products Glance 10
N30 Pharmaceuticals Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
N30 Pharmaceuticals – Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
N30 Pharmaceuticals – Drug Profiles 14
N-6000 Series 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Product Description 15
Mechanism of Action 15
R&D Progress 15
Product Description 16
Mechanism of Action 16
R&D Progress 16
N-9000 Series 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Product Description 18
Mechanism of Action 18
R&D Progress 18
Product Description 19
Mechanism of Action 19
R&D Progress 19
Product Description 20
Mechanism of Action 20
R&D Progress 20
N30 Pharmaceuticals – Pipeline Analysis 21
N30 Pharmaceuticals – Pipeline Products by Therapeutic Class 21
N30 Pharmaceuticals – Pipeline Products By Target 22
N30 Pharmaceuticals – Pipeline Products by Route of Administration 23
N30 Pharmaceuticals – Pipeline Products By Mechanism of Action 24
N30 Pharmaceuticals – Recent Pipeline Updates 25
N30 Pharmaceuticals – Dormant Projects 28
N30 Pharmaceuticals – Locations And Subsidiaries 29
Head Office 29
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/n30-pharmaceuticals-product-pipeline-review-2013.html
Related link : http://www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Call UK +44 7405 208461
Follow us on twitter: https://twitter.com/researchbook
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
ListFree.org: Embedded data.
|Contact us at :|
|Issued By:||sandhya nair|
|Street:||Office No.810, Real Tech Park, 8th Floor, Plot No. 39/2, Sector-30A,Vashi,|
|Phone:||+91 22 27810772|
|Fax:||+91 22 27812290|
|Tags:||N30 Pharmaceuticals, Pharmacueticlas and healthcare|